🟢 Neurosense Therapeutics is trading 9.83% up in pre-market with sector support; cause remains unclear

Neurosense Therapeutics is trading $2.57, up 9.83% in pre-market, with biotech-sector strength providing support while the specific trigger remains unclear.

• Biotech sector is up 3.64% pre-market, but that alone does not establish why shares rose.
• Shares closed at $2.39 on October 20 after several sessions of declines.
• The latest reported news was an October 19 patent application covering potential PrimeC use in traumatic brain injuries; it is not a confirmed cause of the move.